AdAlta Limited (ASX:1AD), an Australian based drug development company, has named Dr Tim Oldham as its new chief executive officer and managing director, it was reported yesterday.
Dr Oldham brings more than 20 years' executive leadership experience to AdAlta. His expertise spans life sciences strategy and business development, commercial and manufacturing operations and alliance management across Europe, Asia and Australia, with a particular focus on biologic and cellular therapies and pharmaceuticals. Prior to AdAlta, Dr Oldham was executive leader at Tijan Ventures. Previous roles have included CEO and managing director of Cell Therapies Pty Ltd, president of Asia Pacific for Hospira Inc, and a variety of senior management roles with Mayne Pharma Ltd in Europe prior to its acquisition by Hospira. These roles include the development and commercialisation of pharmaceuticals, devices, biologics and cellular therapies and industry advocacy. Dr Oldham was also formerly an engagement manager with global strategy consulting firm McKinsey & Co. Presently, Dr Oldham is non-executive director of Acrux Ltd (ASX: ACR) and Immunexus Ltd. He is also a member of the board of BioMelbourne Network Inc.
Executive chairman, Paul MacLeman, said, 'We are delighted to have someone of Tim's calibre and experience join AdAlta as our new chief executive officer. Tim brings a diverse and international skillset, but his biologics and commercialisation expertise will be invaluable as we approach a number of important milestones: non-human primate pre-clinical results, the commencement of phase I human trials for AD-214, and the furthering of late-stage partnering discussions for AdAlta's i-body platform. The board looks forward to working with him to continue to progress our strategy around these value-driving activities.'
Nuevocor names new chief medical officer
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
REVIAN names new vice president of Healthcare Sales
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation
Soligenix announces agreement on design for second Phase 3 trial for HyBryte with EMA
Ratio Therapeutics names new chief business officer and director
Trevi Therapeutics names new vice president of Clinical Development
NeoImmuneTech names new president and chief executive officer